Related Research Articles
The effects of cannabis are caused by chemical compounds in the cannabis plant, including 113 different cannabinoids such as tetrahydrocannabinol (THC) and 120 terpenes, which allow its drug to have various psychological and physiological effects on the human body. Different plants of the genus Cannabis contain different and often unpredictable concentrations of THC and other cannabinoids and hundreds of other molecules that have a pharmacological effect, so that the final net effect cannot reliably be foreseen.
Medical cannabis, or medical marijuana (MMJ), is cannabis and cannabinoids that are prescribed by physicians for their patients. The use of cannabis as medicine has not been rigorously tested due to production and governmental restrictions, resulting in limited clinical research to define the safety and efficacy of using cannabis to treat diseases.
Cannabis, also known as marijuana among other names, is a psychoactive drug from the cannabis plant. Native to Central or South Asia, the cannabis plant has been used as a drug for both recreational and entheogenic purposes and in various traditional medicines for centuries. Tetrahydrocannabinol (THC) is the main psychoactive component of cannabis, which is one of the 483 known compounds in the plant, including at least 65 other cannabinoids, such as cannabidiol (CBD). Cannabis can be used by smoking, vaporizing, within food, or as an extract.
The National Institute on Drug Abuse (NIDA) is a United States federal government research institute whose mission is to "advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health."
Lester Grinspoon was an American psychiatrist and long-standing associate professor of psychiatry at Harvard Medical School best known for his groundbreaking works on the science and social policy of cannabis, psychedelics and other drugs, and for his commitment to changing harmful drug policies. He concurrently served as a senior psychiatrist at the Massachusetts Mental Health Center in Boston, Massachusetts for 40 years. Grinspoon was a fellow of the American Association for the Advancement of Science and the American Psychiatric Association. He was founding editor of The American Psychiatric Association Annual Review and Harvard Mental Health Letter. Grinspoon was editor of Harvard Mental Health Letter for fifteen years.
Cannabis tea is a cannabis-infused drink prepared by steeping various parts of the cannabis plant in hot or cold water. Cannabis tea is commonly recognized as an alternative form of preparation and consumption of the cannabis plant, more popularly known as marijuana, pot, or weed. This plant has long been recognized as an herbal medicine employed by health professionals worldwide to ease symptoms of disease, as well as a psychoactive drug used recreationally and in spiritual traditions. Though less commonly practiced than popular methods like smoking or consuming edibles, drinking cannabis tea can produce comparable physical and mental therapeutic effects. Such effects are largely attributed to the THC and CBD content of the tea, levels of which are drastically dependent on individual preparation techniques involving volume, amount of cannabis, and boiling time. Also in common with these administration forms of cannabis is the heating component performed before usage. Due to the rather uncommon nature of this particular practice of cannabis consumption in modern times, the research available on the composition of cannabis tea is limited and based broadly around what is known of cannabis as it exists botanically.
In the United States, the non-medical use of cannabis is legalized in 21 states and decriminalized in 10 states, as of January 2023. Decriminalization refers to a policy of reduced penalties for cannabis offenses, typically involving a civil penalty for possessing small amounts, instead of criminal prosecution or the threat of arrest. In jurisdictions without penalty the policy is referred to as legalization, although the term decriminalization is sometimes used for this purpose as well.
Drug liberalization is a drug policy process of decriminalizing or legalizing the use or sale of prohibited drugs. Variations of drug liberalization include: drug legalization, drug re-legalization and drug decriminalization. Proponents of drug liberalization may favor a regulatory regime for the production, marketing, and distribution of some or all currently illegal drugs in a manner analogous to that for alcohol, caffeine and tobacco.
The long-term effects of cannabis have been the subject of ongoing debate. Because cannabis is illegal in most countries, clinical research presents a challenge and there is limited evidence from which to draw conclusions. In 2017, the U.S. National Academies of Sciences, Engineering, and Medicine issued a report summarizing much of the published literature on health effects of cannabis, into categories regarded as conclusive, substantial, moderate, limited and of no or insufficient evidence to support an association with a particular outcome.
Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and ICD-10 as the continued use of cannabis despite clinically significant impairment.
Barbara Jacquelyn Sahakian, is Professor of Clinical Neuropsychology at the Department of Psychiatry and Medical Research Council (MRC)/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge. She is also an Honorary Clinical Psychologist at Addenbrooke's Hospital, Cambridge. She has an international reputation in the fields of cognitive psychopharmacology, neuroethics, neuropsychology, neuropsychiatry and neuroimaging.
Professor David Wayne Johnson is an Australian nephrologist known for kidney treatments and transplants in Australia. In 2009 he was a Queensland State Finalist for Australian of the Year, for his work in the early recognition and care of people with chronic kidney disease and specifically for his work in detection of chronic kidney disease.
The Australian National Task Force on Cannabis (NTFC) was a specialised unit formed in April 1992 under the aegis of the Ministerial Council on Drug Strategy (MCDS) who are responsible for implementing national consistency in policy principles related to Australia's National Drug Strategy.
Professor Maree Rose Teesson AC, FAAHMS, FASSA, is an Australian expert on mental health. She is the Director of The Matilda Centre for Research in Mental Health and Substance Use and NHMRC Principal Research Fellow at the University of Sydney. She is also professorial fellow at the Black Dog Institute, UNSW.
Two main questions arise in the law surrounding driving after having ingested cannabis: (1) whether cannabis actually impairs driving ability, and (2) whether the common practice of testing for THC is a reliable means to measure impairment. On the first question, studies are mixed. Several recent, extensive studies–including one conducted by the National Highway Traffic Safety Administration and one conducted by the American Automobile Association (AAA)–show that drivers with detectable THC in their blood are no more likely to cause car crashes than drivers with no amount of THC in their blood. Others show that cannabis can impair certain abilities important to safe driving –but no studies have been able to show that this increases the actual risk of crashing, or that drivers with THC in their blood cause a disproportionate number of crashes. On the second question, the studies that have been conducted so far have consistently found that THC blood levels and degree of impairment are not closely related. No known relationship between blood levels of THC and increased relative crash risk, or THC blood levels and level of driving impairment, has been shown by single-crash or classic-control studies. Thus, even though it is possible that cannabis impairs driving ability to some extent, there are currently no reliable means to test or measure whether a driver was actually impaired.
Occupational health concerns over the use of cannabis among workers are becoming increasingly important as cannabis becomes legal in more areas of the US. Of note, employers have concerns of workers either coming to work acutely impaired or recent use of cannabis still being detected in the body. Employment issues such as ADA law as it relates to accommodations for cannabis, paying unemployment benefits or paying out workers compensation benefits and disability claims are all important issues. While federal law still prohibits use, employers in different states have taken different stances based on whether they are federal contractors, perform safety sensitive work or whether the cannabis use is acutely impairing the employee.
Professor Anne Kelso is an Australian biomedical researcher specialising in immunology and influenza. She is the Chief Executive Officer of the Australian Government's National Health and Medical Research Council (NHMRC).
Kaarin Anstey is an Australian Laureate Fellow and one of Australia's top dementia scientists. She is Co-Deputy Director of the ARC Centre of Excellence in Population Ageing Research (CEPAR) at the University of New South Wales, Australia, where she is Scientia Professor of Psychology. Kaarin Anstey is an Honorary Professor at the Australian National University and a Fellow of the Academy of the Social Sciences in Australia. She is a Director of the NHMRC Dementia Centre for Research Collaboration, Senior Principal Research Scientist at NeuRA and leads the NHMRC Centre of Research Excellence in Cognitive Health and the UNSW Ageing Futures Institute.
Lisa Maher is Professor and head of Viral Hepatitis Epidemiology, at the Kirby Institute for Infection and Immunity, at the University of New South Wales and was made Member of the Order of Australia in 2015. She was awarded an Elizabeth Blackburn Fellowship, in Public Health from the NHMRC, in 2014. She is a fellow of the Australian Academy of Health and Medical Sciences.
Jennifer Helen Martin is an Australian clinical pharmacologist, physician and academic. She is chair of Clinical Pharmacology in the University of Newcastle School of Medicine and Public Health, Director of the NHMRC funded Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), and an elected a Fellow of the Australian Academy of Health and Medical Sciences. Martin translates research into practice and policy. Her research involves the investigation of therapeutic drugs, from drug design and development, to clinical trials and studies to investigate how new drugs perform in the general population.
References
- ↑ "ISI Web of Knowledge". Archived from the original on 19 May 2007. Retrieved 11 February 2008.
- ↑ Hall, Wayne (January 2015). "What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?" (PDF). Addiction. 110 (1): 19–35. doi:10.1111/add.12703. PMID 25287883.
- ↑ Wofford, Taylor (7 October 2014). "The Good, the Bud and the Ugly: What 20 Years of Research Teaches Us About Cannabis". Newsweek. Retrieved 7 October 2014.
- ↑ Engel, Meredith (7 October 2014). "Marijuana can cause mental disorders, loss of intelligence: 20-year study". New York Daily News. Retrieved 7 October 2014.
- ↑ "Fellowship of the Australian Academy of Health & Medical Sciences - October 2015" (PDF). Australian Academy of Health & Medical Sciences. Retrieved 12 October 2018.
| General | |
|---|---|
| National libraries | |
| Other | |
